EGFR and gastric cancer: Similarly, other studies have been carried with the use of anti-EGFR therapies for gastric cancer patients with EGFR amplification and/or patients who are EGFR positive with IHC after the surgical resection of primary tumor [46], showing that EGFR positivity is an independent favorable prognostic factor, especially in stage III disease [46].